financetom
Business
financetom
/
Business
/
Endeavor Group Holdings Insider Sold Shares Worth $514,777, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Endeavor Group Holdings Insider Sold Shares Worth $514,777, According to a Recent SEC Filing
Mar 15, 2024 6:03 AM

08:36 AM EDT, 03/15/2024 (MT Newswires) -- Jason Lublin, Chief Financial Officer, on March 12, 2024, sold 41,664 shares in Endeavor Group Holdings ( EDR ) for $514,777. Following the Form 4 filing with the SEC, Lublin has control over a total of 130,187 shares of the company, with 130,187 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1766363/000095017024031797/xslF345X03/ownership.xml

Price: 25.1, Change: -0.06, Percent Change: -0.24

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amylyx Pharmaceuticals Launches Stock Offering
Amylyx Pharmaceuticals Launches Stock Offering
Jan 10, 2025
04:31 AM EST, 01/10/2025 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said late Thursday it has commenced an underwritten public offering of common shares. Amylyx plans to give the underwriter a 30-day option to buy up to an additional 15% of the shares offered. The company said the proceeds will be used to support commercialization, pipeline programs, working capital...
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform
Jan 10, 2025
04:39 AM EST, 01/10/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said late Thursday it has struck a licensing agreement to use MediLink Therapeutics' Tmalin antibody-drug conjugate platform for the development of its ZL-6201 investigational drug. Financial terms were not disclosed. Zai Lab ( ZLAB ) said the partnership will expand its oncology pipeline with another drug targeting multiple...
Thermo Fisher Scientific Says Olink Platform Chosen by UK Proteomics Project
Thermo Fisher Scientific Says Olink Platform Chosen by UK Proteomics Project
Jan 10, 2025
04:21 AM EST, 01/10/2025 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) said late Thursday the UK Biobank Pharma Proteomics Project has chosen its Olink Explore Platform to support a human proteomics study. Financial terms were not disclosed. The project will analyze more than 5,400 proteins from 600,000 samples to help find new biomarkers that could potentially identify, diagnose...
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth
Jan 10, 2025
04:39 AM EST, 01/10/2025 (MT Newswires) -- Innate Pharma ( IPHA ) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases. The company said it is currently testing its NK Cell Engager, IPH6501, in a phase 1/2 trial for non-Hodgkin's lymphoma. Additionally, Innate said it is advancing its Antibody-Drug...
Copyright 2023-2026 - www.financetom.com All Rights Reserved